Tag: AMW GmbH

9. November 2021

AMW and AdhexPharma announce strategic partnership for transdermal delivery systems

Today a strategic partnership between AMW GmbH and AdhexPharma SAS on AMW’s transdermal delivery systems technology platform and product portfolio was announced, combining the strengths of both companies in the field of TDS. Under the partnership, AMW will focus on development, marketing authorization and licensing of novel transdermal delivery systems. AdhexPharma will focus on the commercial manufacturing and lifecycle management of the products. AdhexPharma will take over the manufacturing equipment and the IP for AMW’s products Buprenorphine and Rivastigmine and following a transition phase of up to 30 months the contract manufacturing of these Products from AMW.

19. October 2021

AMW signs license and supply agreements for the commercialization of its goserelin and leuprorelin implants in Israel

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, announced today that license and supply agreements (LSAs) have been signed with an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in Israel.

26. December 2019

AMW GmbH from Warngau continues to grow and establishes an advisory board

More than 100 people are now employed at the pharmaceutical plant in Warngau. In addition to the implants Goserelin and Leuprorelin and the patches Buprenorphin and Rivastigmine, the specialty pharmaceutical company developed a generic version of MSD’s Nuvaring contraceptive ring to market maturity. AMW is thus setting new standards in contraception. In order to improve its scientific and technical position, AMW has established an advisory board consisting of Dr. Georg Ingram, Dr. Dirk Schrader and Prof. Dr. Gerhard Winter.